Scaling new heights in the fight against heart disease
We are focused on advancing our clinical-stage lead gene therapy programs, TN-201 for MYBPC3-associated HCM and TN-401 for PKP2-associated ARVC.
We are a biotechnology company committed to a bold mission: to discover, design, develop and deliver potentially curative therapies that address the underlying drivers of heart disease.
Founded by leading cardiovascular scientists, our team has the tenacity to pursue our ultimate peak – changing the treatment paradigm for heart disease, and in doing so improving and extending the lives of millions of individuals and families fighting these debilitating conditions.
LATEST NEWS
Tenaya Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Received Regenerative Medicine Advanced Therapy (RMAT) Designation from U.S. FDA for TN-401 Gene Therapy for PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy TN-201 and TN-401 Program Updates on Upcoming Data Readouts and Regulatory Interactions for Pivotal Trial Planning Anticipated
Read MoreTenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
RMAT Designation Supported by Positive Interim Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 which Demonstrated Reduced Arrhythmia Burden Additional Data and Updates on Regulatory Discussions Anticipated in 4Q 2026 SOUTH SAN FRANCISCO, Calif., Sept.
Read MoreTenaya Therapeutics to Participate in Upcoming September Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that
Read More
PATIENTS FIRST
Here at Tenaya, we strive to make the needs of patients our top priority in all we do. As we develop new medicines aimed at targeting the genetic underpinnings of cardiomyopathies, we’ve sought input from patients and their families all along the way to better understand how genetic conditions like hypertrophic cardiomyopathy and arrhythmogenic right ventricular impact their lives daily and over time. We’ve also created resources to help patients, their families and their physicians better understand how gene therapies work and what to expect from our clinical trials.